Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 1, 1999, Pages 4-8

  Bennett, C L ^a   Tosteson, T D ^b   Schmitt, B ^a   Weinberg, P D ^a   Ernstoff, M S ^c   Ross, S D ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d MetaWorks Inc   (United States)

Author keywords

Flutamide; Maximum androgen blockade; Meta analysis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; FLUTAMIDE; LEUPRORELIN; NILUTAMIDE; TRIPTORELIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; TREATMENT OUTCOME;

EID: 0033014347     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500265     Document Type: Article

References (28)

1. Labrie F, DuPont A, Belanger A. New approach in the treatment of prostatic cancer. Complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579-594.
2. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-269.
3. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. NEJM 1998; 339: 1036-1042.
4. Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. NEJM 1989; 321: 419-424.
5. Caubet JF et al. Maximum androgen-blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using non-steroidal antiandrogens. Urology 1997; 49: 71-78.
6. Tyrell CJ et al. A multicenter randomized trial comparing the lutenizing hormone-releasing hormone analog goserelin acetate alone with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. J Urol 1991; 146: 1321-1326.
7. Boccardo F et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer: The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 1993; 29A: 1088-1093.
8. Denis LJ et al. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). EORTC GU Group and EORTC data Center. Urology 1193; 42: 119-130.
9. Bono AV et al and the members of the Italian Leuprolide Group. Complete androgen blockade versus chemical castration in advanced prostatic cancer: Analysis of an Italian multicentre study. Urol Int 1998; 60 (suppl 1): S18-S24.
10. Schulze H, Kaldenoff H, Senge T. Evaluation of total versus partial androgen blockade in the treatment of advanced prostate cancer. Urol Int 1988; 43: 193-197.
11. Denis L et al. Orchidectomy versus zoladex plus eulexin in patients with metastatic prostate cancer. (EORTC 30853). J Steroid Biochem Mol Biol 1990; 37: 951-995.
12. Iverson P et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 1990; 66: 1058S-1066S.
13. Fourcade RO et al. Total androgen blockade with zoladex plus flutamide versus zoladex plus placebo in advanced prostatic carcinoma: interim report, of a multi-center double-blind placebo-controlled study. Eur Urol 1990; 18: 45S-47S.
14. Fourcade RO et al. Zoladex plus flutamide versus zoladex plus placebo in advanced prostatic carcinoma: extended follow-up of the French multi-center study. In: Murphy G and Khoury S (eds). Proceedings of the Third International Symposium on Recent Advances in Urological Cancers. 1993; pp 102-106.
15. Zalcberg JR, Raghaven D, Marshall V, Thompson PJ. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate - an Australian multicentre trial. BR J Urol 1996; 77: 865-869.
16. Whitehead A, Whitehead J. A general parametric approach to randomized clinical trials. Stat in Med 1991; 10: 1665-1667.
17. Miller RG. Survival Analysis. Wiley Inc.: New York, 1982.
18. DeSimonian R, Laird N. Meta-analysis in controlled trials. Controlled Clin Trials 1986; 7: 177-188.
19. Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A. Combination treatment versus LhRH alone in advanced prostate cancer. Urologia Internationalis 1996; 56 (Suppl 1): S13-S17.
20. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized controlled trials. Ann Intern Med 1995; 123: 873-877.
21. LeLorier J et al. Discrepancies between meta-analyses and subsequent large randomized controlled trials. N Engl J Med 1997; 337: 536-542.
22. Jeng GT, Scott JR, Brumeister LF. A comparison of meta-analytic results using literature versus individual patient data: paternal cell immunization for recurrent miscarriage. JAMA 1995; 274: 830-836.
23. Ionnidis JP, Capperleri JC, Lau J. Issues in comparisons between meta-analysis and large trials. JAMA 1998; 279: 1089-1093.
24. Cappelleri JC et al. Large trials versus meta-analysis of smaller trials: how do they compare? JAMA 1996; 276: 1332-1338.
25. Chalmer I. The Cochrane Collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann NY Acad Sci 1993; 703: 156-165.
26. Oxman A, Clarke M, Steward L. From science to practice: meta-analyses using individual patient data are needed. JAMA 1995; 274: 845-846.
27. Sucui S et al. Comparability of trials in prostate cancer. Cancer 1993; 72: 3841-3846.
28. Hillner BE, McLcod DG, Crawford ED, Bennett CL. Estimating the cost-effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995; 45: 633-640.